X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (119) 119
male (56) 56
cardiac & cardiovascular systems (53) 53
female (53) 53
middle aged (51) 51
aged (39) 39
hematology (36) 36
thrombolytic therapy (33) 33
acute myocardial-infarction (28) 28
medicine, general & internal (25) 25
fibrinolytic agents - therapeutic use (22) 22
myocardial infarction - drug therapy (22) 22
index medicus (20) 20
myocardial infarction - therapy (18) 18
peripheral vascular disease (18) 18
unstable angina (18) 18
adult (17) 17
angioplasty, balloon, coronary (17) 17
coronary disease - therapy (17) 17
recurrence (17) 17
risk factors (17) 17
time factors (17) 17
angioplasty (16) 16
treatment outcome (16) 16
acute coronary syndromes (15) 15
cardiology (14) 14
coronary angiography (14) 14
hemorrhage - chemically induced (14) 14
heparin (14) 14
prognosis (14) 14
prospective studies (14) 14
tissue plasminogen activator - therapeutic use (14) 14
biochemistry & molecular biology (13) 13
trial (13) 13
anticoagulants - therapeutic use (12) 12
coronary heart disease (12) 12
drug therapy, combination (12) 12
myocardial infarction - mortality (12) 12
platelet aggregation inhibitors - therapeutic use (12) 12
restenosis (12) 12
therapy (12) 12
anticoagulation (11) 11
follow-up studies (11) 11
acute disease (10) 10
animals (10) 10
anticoagulants - adverse effects (10) 10
coronary disease - drug therapy (10) 10
fibrinolytic agents - adverse effects (10) 10
myocardial-infarction (10) 10
thrombolysis (10) 10
acute coronary syndrome (9) 9
aspirin (9) 9
atrial fibrillation (9) 9
cardiovascular system (9) 9
electricity (9) 9
management (9) 9
medicine & public health (9) 9
molecular-weight heparin (9) 9
plasminogen-activator (9) 9
risk assessment (9) 9
stroke (9) 9
thrombosis - drug therapy (9) 9
tissue plasminogen-activator (9) 9
analysis (8) 8
artery disease (8) 8
coronary artery bypass (8) 8
guidelines (8) 8
heparin - administration & dosage (8) 8
heparin - adverse effects (8) 8
heparin - therapeutic use (8) 8
hospital mortality (8) 8
mortality (8) 8
myocardial infarction (8) 8
plasminogen activators - therapeutic use (8) 8
thrombosis (8) 8
tissue plasminogen activator - administration & dosage (8) 8
unfractionated heparin (8) 8
angina, unstable - drug therapy (7) 7
angina, unstable - therapy (7) 7
anticoagulants (7) 7
basic electric elements (7) 7
care and treatment (7) 7
cells, cultured (7) 7
diagnosis (7) 7
dose-response relationship, drug (7) 7
electrocardiography (7) 7
fibrinolytic agents - administration & dosage (7) 7
medicine, research & experimental (7) 7
myocardial infarction - blood (7) 7
outcomes (7) 7
percutaneous coronary intervention (7) 7
plasminogen activators - administration & dosage (7) 7
prevention (7) 7
randomized controlled trials as topic (7) 7
randomized trial (7) 7
rate control (7) 7
signal transduction (7) 7
sudden cardiac death (7) 7
syndrome (7) 7
acute coronary syndrome - therapy (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2015, Volume 128, Issue 7, pp. 766 - 775
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2007, Volume 49, Issue 23, pp. 2238 - 2246
Journal Article
by Beyer-Westendorf, Jan and Camm, A. John and Fox, Keith A. A and Le Heuzey, Jean-Yves and Haas, Sylvia and Turpie, Alexander G. G and Virdone, Saverio and Kakkar, Ajay K and Pieper, Karen S and Kayani, Gloria and Gersh, Bernard J and Hildebrandt, P and Dominguez, H and Comuth, W and Frost, L and Moller, D.S and Christensen, H and Bruun, L.M and Milhem, A and Gauthier, J and Mielot, C and Chanseaume, S and Chopra, S and Amlaiky, A and Tricot, O and Sierra, V and Dompnier, A and Zannad, N and Pinzani, A and Quatre, A and Mansourati, J and Fauchier, L and Badenco, N and Gandjbakhch, E and Chachoua, K.F and Malquarti, V and Pierron, F and Sacher, F and Taieb, J and Davy, J.M and Marijon, E and Lellouche, N and Leenhardt, A and Salem, A and Lesto, I and Muller, J.J and Garcia, R and Neau, J.P and Berneau, J.B and Schön, N and Gulba, D and Appel, K.F and Merke, J and Dshabrailov, J and Bauknecht, C and Scheuermann, O and Schröder, T and Jung, W and Kopf, A and Brachmann, J and Leschke, M and Taggeselle, J and Seige, M and Läßig, T and Appel, S and Schmiedl, M and Müller, K and Heinz, G.U and Axthelm, C and Eberhard, K and Hügl, B and Schwarz, T and Sechtem, U and Falanga, A and Rubino, V and Calo, L and Ageno, W and Massari, F and Imberti, D and Di Gennaro, L and Gaita, F and Margonato, A and Cannava, G and Capasso, F and Diemberger, I and Pelliccia, F and Cafolla, A and Bardari, S and Mattei, L and Ruocco, L and Boriani, G and Poli, D and Testa, S and Indolfi, C and Quintavalla, R and Mos, L and Ladyjanskaia, G and Aksoy, I and Van De Wetering, M and Theunissen, L and ... and RIVER Registry Investigators and for the RIVER Registry Investigators
Thrombosis Journal, ISSN 1477-9560, 04/2019, Volume 17, Issue 1, pp. 7 - 11
Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate... 
Rivaroxaban | Anticoagulant | Registry | Atrial fibrillation | Outcomes | Antithrombotic | Stroke (Disease) | Care and treatment | Mortality | Dosage and administration | Information management | Health aspects | Studies | Anticoagulants | Stroke | Emergency medical care
Journal Article